Search Contract Opportunities

Intent to Sole Source Specific Pathogen Free Fertile Eggs

ID: 75D301-25-Q-78570 • Type: Presolicitation

Description

The Center for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases Influenza Division (NCIRD/ID), intends to award a sole source purchase order in accordance with FAR 13.106-1(b)(1), soliciting from a single source, to Avian Vaccine Services LLC, Address: 1 Wisconsin Avenue, Suite 100, Norwich, CT 06360, for Specific Pathogen Free Fertile Eggs. The objective of this requirement is for the contractor to furnish research-specific pathogen-free (SPF) eggs to the NCIRD/ID as recommended for the production of high-growth reassortant influenza candidate vaccine viruses and live attenuated influenza virus vaccine candidates by the World Health Organization (WHO). The NAICS code for this procurement is 112310, Chicken Egg Production.

The WHO recommends that influenza vaccine seed candidates are produced in SPF-embryonated chicken eggs. The vaccine seed candidates must have the antigenic properties of the recommended strain and improved growth properties for more efficient vaccine production. The use of SPF eggs from Avian Vaccine Services has resulted in the successful production of candidate vaccine viruses in the past and has optimized laboratory protocols. Genetics vary between the chicken flocks that supply SPF eggs. Additionally, variations of the microbiome among supplier flocks are expected. Obtaining genetically distinct SPF eggs from alternate suppliers may lead to changes in the isolation rate and potential quality of resulting isolates. This could risk the ability of the Influenza Division to provide candidate vaccine egg viruses to manufacturers in a timely fashion.

As a result of this notice, no competitive solicitation will be posted on SAM.gov. The government will issue only one solicitation to Avian Vaccine Services LLC. However, firms that believe they can meet this requirement are encouraged to identify themselves and give written notice by providing a capability statement to the contract specialist, Dawnnia Daley, at xwf5@cdc.gov by December 5, 2024, at 5:00 p.m. ET. The contract specialist will not respond to verbal requests. All requests must be in writing.

A determination by the government not to take this proposed action will be based on responses to this notice and is solely within the discretion of the contracting officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Inquiries shall reference the solicitation number, 75D301-25-Q-78570, on the subject line and be sent to Dawnnia Daley by email at xwf5@cdc.gov.

Overview

Response Deadline
Dec. 5, 2024, 5:00 p.m. EST Past Due
Posted
Nov. 20, 2024, 12:32 p.m. EST
Set Aside
None
Place of Performance
Atlanta, GA 30345 United States
Source
SAM

Current SBA Size Standard
$19 Million
Est. Level of Competition
Sole Source
Odds of Award
21%
On 11/20/24 Centers for Disease Control and Prevention issued Presolicitation 75D301-25-Q-78570 for Intent to Sole Source Specific Pathogen Free Fertile Eggs due 12/5/24. The opportunity was issued full & open with NAICS 112310 and PSC AJ13.
Primary Contact
Name
Dawnnia Daley   Profile
Email
Phone
(404) 498-6079

Secondary Contact

Name
Liubov Kriel   Profile
Email
Phone
(770) 488-2856

Documents

Posted documents for Presolicitation 75D301-25-Q-78570

Question & Answer

Incumbent or Similar Awards

Contracts Similar to Presolicitation 75D301-25-Q-78570

Potential Bidders and Partners

Awardees that have won contracts similar to Presolicitation 75D301-25-Q-78570

Similar Active Opportunities

Open contract opportunities similar to Presolicitation 75D301-25-Q-78570

Additional Details

Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > CENTERS FOR DISEASE CONTROL AND PREVENTION > CDC OFFICE OF ACQUISITION SERVICES
FPDS Organization Code
7523-00254
Source Organization Code
100188028
Last Updated
Dec. 21, 2024
Last Updated By
vyh1@cdc.gov
Archive Date
Dec. 20, 2024